GSK3B and neoplasm: Metavert is a dual inhibitor that was developed to inhibit GSK3-β driven tumor-promotion via NF-κB activation, as well as blocking histone deacetylase (HDAC) classes to interfere with epithelial to mesenchymal transition (EMT), which otherwise would be enhanced by GSK3-β inhibition [[16], [17], [18], [19], [20], [21], [22], [23]].